A new report suggests biotech took the lead in UK healthcare M&A in 2025, outpacing pharma and life sciences.

Organisations like Phesi are leveraging digital patient profiles to create digital twins for even the rarest diseases.

Meeting new EU targets for clinical trials could grant 35,000 additional patients access to novel treatments according to a new report.

UCB backs Refold Therapeutics to tackle light chain amyloidosis, a rare disease damaging the heart and kidneys.

The deal is a unified effort to advance a CAR T-cell therapy currently under regulatory review for multiple myeloma.

The FDA has announced that a single clinical trial will now be the default requirement for the approval of novel medicines.

James Van Der Beek’s death from bowel cancer has thrust rising colorectal cancer rates back into the spotlight.

The initiative aims to provide elite athletes with targeted rehabilitation and holistic care for complex or extended recovery needs.